Peel Hunt Reaffirms Buy Rating for PureTech Health (LON:PRTC)

PureTech Health (LON:PRTC)‘s stock had its “buy” rating restated by Peel Hunt in a research report issued to clients and investors on Monday,London Stock Exchange reports. They presently have a GBX 508 price target on the stock. Peel Hunt’s target price would suggest a potential upside of 309.02% from the company’s previous close.

PureTech Health Price Performance

LON:PRTC traded up GBX 3.29 on Monday, reaching GBX 124.20. 217,160 shares of the company’s stock traded hands, compared to its average volume of 1,138,141. The stock has a 50-day simple moving average of GBX 129.60 and a 200-day simple moving average of GBX 127.04. The firm has a market cap of £302.33 million, a PE ratio of -2.70 and a beta of 0.79. PureTech Health has a 12 month low of GBX 104.71 and a 12 month high of GBX 148. The company has a quick ratio of 2.51, a current ratio of 6.59 and a debt-to-equity ratio of 6.33.

Insider Transactions at PureTech Health

In other PureTech Health news, insider Robert Lyne acquired 36,500 shares of the stock in a transaction on Tuesday, July 7th. The stock was acquired at an average price of GBX 119 per share, for a total transaction of £43,435. Also, insider Sharon Barber-Lui bought 29,868 shares of the company’s stock in a transaction dated Tuesday, July 7th. The stock was bought at an average price of GBX 119 per share, with a total value of £35,542.92. Insiders have bought a total of 147,849 shares of company stock valued at $17,594,031 over the last quarter. 13.35% of the stock is owned by insiders.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia.